Avalo Therapeutics begins Phase 2 LOTUS trial of AVTX-009 for treating hidradenitis suppurativa.

Avalo Therapeutics has initiated the Phase 2 LOTUS trial, dosing its first patient with AVTX-009, a monoclonal antibody targeting interleukin-1β, for treating hidradenitis suppurativa (HS). The study will involve 180 adults with moderate to severe HS and will compare the drug's efficacy and safety against a placebo. Results are anticipated in 2026, marking a potential advancement in HS treatment.

October 08, 2024
3 Articles